Home › Funds › Maven Securities LTD › APGE
Maven Securities LTD position in APGE
APOGEE THERAPEUTICS INC
Maven Securities LTD reported holding 115,018 shares of APGE (APOGEE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$15.3M, representing 1.07% of its reported portfolio and ranking #22 among its reported holdings. Maven Securities LTD has disclosed APGE holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Maven Securities LTD's APGE position evolved
Maven Securities LTD first disclosed a stake in APGE in Q1 2026 at 25,000 shares (US$2.1M). The position peaked in Q2 2026 at 115,018 shares, worth US$15.3M. Across 2 filings, Maven Securities LTD increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 115,018 shares valued at US$15.3M — an increase of 90,018 shares quarter over quarter.. Notable position changes include a 360% increase in Q2 2026.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 25.00K | $2.10M | New |
| Q2 2026 | 115.02K | $15.27M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About APGE and 13F data
APGE (APOGEE THERAPEUTICS INC) is a company whose sector is not yet classified in our data. 60 other funds we track also report a position in APGE — the largest reported positions include Venrock Adviser, LLC (US$1.13B), HBK INVESTMENTS L P (US$378.3M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$231.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding APGE
- Venrock Adviser, LLC 8.49M sh · $1.13B · Q2 2026
- HBK INVESTMENTS L P 2.85M sh · $378.28M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.74M sh · $230.96M · Q2 2026
- GLAZER CAPITAL, LLC 1.64M sh · $217.82M · Q2 2026
- Paradigm Biocapital Advisors LP 1.58M sh · $209.23M · Q2 2026
- Pentwater Capital Management LP 1.43M sh · $189.14M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.31M sh · $173.63M · Q2 2026
- Affinity Asset Advisors, LLC 987.00K sh · $131.00M · Q2 2026
- First Light Asset Management, LLC 930.29K sh · $123.48M · Q2 2026
- Kryger Capital LLC 742.55K sh · $98.56M · Q2 2026
- First Trust Capital Management L.P. 625.18K sh · $82.98M · Q2 2026
- Remedium Capital Partners, LLC 586.69K sh · $77.87M · Q2 2026
More on Maven Securities LTD
FAQ
How long has Maven Securities LTD held APGE?
Maven Securities LTD has disclosed APGE holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Maven Securities LTD's current position in APGE?
As of Q2 2026, Maven Securities LTD holds 115.02K shares of APGE (APOGEE THERAPEUTICS INC), valued at $15.27M, representing 1.07% of its reported portfolio and ranking #22.
Has Maven Securities LTD been buying or selling APGE?
In the latest 13F filing (Q2 2026), Maven Securities LTD increased its position in APGE. The position peaked in Q2 2026 at 115.02K shares.
Which other funds hold APGE?
Other major institutional holders of APGE include Venrock Adviser, LLC, HBK INVESTMENTS L P, DRIEHAUS CAPITAL MANAGEMENT LLC, among 60 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.